Launxp, a biotech company focused on innovative therapies, has announced a strategic partnership with precision manufacturing leader Darwin to co-develop a Microcrystal patch-based Semaglutide product.
This next-generation drug delivery system is designed to offer a convenient, pain-free alternative for patients managing type 2 diabetes and obesity.
Semaglutide, traditionally administered via injection, has seen rapid market growth but faces challenges related to patient compliance and comfort.
The Microcrystal patch technology developed by Launxp allows for transdermal delivery via micron-scale structures that painlessly penetrate the skin’s outer layer, increasing drug absorption while reducing discomfort and infection risk.
Darwin contributes advanced microstructure molding and scalable automated manufacturing processes, ensuring high consistency, reliability, and production efficiency.
With global obesity and diabetes rates surging, the collaboration targets a fast-growing market with immense potential.
The World Obesity Federation projects 1.13 billion obese adults by 2030, while GLP-1 drug sales—led by Semaglutide—continue to grow rapidly.
This partnership exemplifies cross-industry innovation, combining biomedical R&D with precision manufacturing to redefine chronic disease treatment and set a new benchmark for needle-free drug delivery technologies.
